57 related articles for article (PubMed ID: 38721105)
1. Insight into the regulatory mechanism of m
Zha X; Gao Z; Li M; Xia X; Mao Z; Wang S
Biomed Pharmacother; 2024 Jun; 177():116966. PubMed ID: 38906018
[TBL] [Abstract][Full Text] [Related]
2. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.
Karin M; Kim JY
Mol Oncol; 2024 Jun; ():. PubMed ID: 38874196
[TBL] [Abstract][Full Text] [Related]
3. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
4. Should we undertake surveillance for HCC in patients with MAFLD?
Norero B; Dufour JF
Ther Adv Endocrinol Metab; 2023; 14():20420188231160389. PubMed ID: 37006779
[TBL] [Abstract][Full Text] [Related]
5. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention.
Anwar WA; Khaled HM; Amra HA; El-Nezami H; Loffredo CA
Mutat Res; 2008; 659(1-2):176-84. PubMed ID: 18346933
[TBL] [Abstract][Full Text] [Related]
6. Changes in the Etiologies of Liver Cancer in Upper Egypt over a Decade from 2010 to 2020: A Single Tertiary Care Center Study.
Fouad Y; Gaber Y; Alem SA; Abdallah M; Abd-Elsalam SM; Nafady S; Attia D; Eslam M
South Asian J Cancer; 2024 Jan; 13(1):10-16. PubMed ID: 38721105
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.
Yang DL; Liu SP; Wang HL; Li JR; Su JY; Li MJ; Teng YX; Deng ZJ; Li ZH; Huang JL; Guo PP; Ma L; Li ZZ; Zhong JH
Infect Agent Cancer; 2024 May; 19(1):21. PubMed ID: 38693556
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in Egypt: a single center study over a decade.
el-Zayadi AR; Badran HM; Barakat EM; Attia Mel-D; Shawky S; Mohamed MK; Selim O; Saeid A
World J Gastroenterol; 2005 Sep; 11(33):5193-8. PubMed ID: 16127751
[TBL] [Abstract][Full Text] [Related]
10. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
11. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study.
Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
Hepatol Res; 2022 Dec; 52(12):975-984. PubMed ID: 35976670
[TBL] [Abstract][Full Text] [Related]
12. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.
Fouad Y; Lazarus JV; Negro F; Peck-Radosavljevic M; Sarin SK; Ferenci P; Esmat G; Ghazinian H; Nakajima A; Silva M; Lee S; Colombo M
Aliment Pharmacol Ther; 2021 May; 53(10):1080-1089. PubMed ID: 33751604
[TBL] [Abstract][Full Text] [Related]
13. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.
Shiha G; Alswat K; Al Khatry M; Sharara AI; Örmeci N; Waked I; Benazzouz M; Al-Ali F; Hamed AE; Hamoudi W; Attia D; Derbala M; Sharaf-Eldin M; Al-Busafi SA; Zaky S; Bamakhrama K; Ibrahim N; Ajlouni Y; Sabbah M; Salama M; Anushiravani A; Afredj N; Barakat S; Hashim A; Fouad Y; Soliman R
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):57-64. PubMed ID: 33181119
[TBL] [Abstract][Full Text] [Related]
14. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
Eslam M; Sarin SK; Wong VW; Fan JG; Kawaguchi T; Ahn SH; Zheng MH; Shiha G; Yilmaz Y; Gani R; Alam S; Dan YY; Kao JH; Hamid S; Cua IH; Chan WK; Payawal D; Tan SS; Tanwandee T; Adams LA; Kumar M; Omata M; George J
Hepatol Int; 2020 Dec; 14(6):889-919. PubMed ID: 33006093
[TBL] [Abstract][Full Text] [Related]
15. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2021 Feb; 74(2):303-311. PubMed ID: 32931878
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
